

Press release

Zug, 30 September 2008

Disclosure of shareholdings in accordance with Articles 9 and 17 of the Federal Act on Stock Exchanges and Securities Trading – SFBC

HBM BioVentures Ltd (SWX: HBMN), Zug, announces that on 26 September 2008 it received a communication from Pictet & Cie (nominee), route des Acacias 60, 1211 Geneva, acting on behalf of Rolex Holding, rue François-Dussaud 3-7, 1211 Geneva, stating that Rolex Holding has fallen below the threshold of 3% of the voting rights as a result of the sale of registered shares of HBM BioVentures. In addition, HBM BioVentures Ltd received a communication on 26 September 2008 from Pictet & Cie (nominee), acting on behalf of Rolex Holding, according to which Rolex Holding was the economic beneficiary of 350'000 registered shares, equal to 3.1%, on 14 February 2008, at the time of the listing of HBM BioVentures on the SWX Swiss Exchange. The charitable Foundation Hans Wilsdorf Genève, Place d'Armes 20, 1227 Carouge, owns 100% of Rolex Holding.

For further information, please contact Dr. Joachim Rudolf, CFO HBM BioVentures Ltd, tel.: +41 41 768 11 08, joachim.rudolf@hbmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds of its CHF 1 billion capital invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SWX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation. A public share offer in the USA would be conducted by means of a prospectus that would be available from HBM BioVentures Ltd and would contain detailed information about the company and its management, as well as the annual financial statements.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com